Yescarta®▼ (axicabtagene ciloleucel)
Yescarta® is indicated for the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy.
Yescarta® is indicated for the treatment of adult patients with relapsed or refractory (R/R) DLBCL and primary mediastinal large B-cell lymphoma (PMBCL), after two or more lines of systemic therapy.
Explore clinical efficacy and safety data in:
DLBCL second-line or more
Tecartus®▼ (brexucabtagene autoleucel)
Tecartus® has been granted conditional marketing authorisation and is indicated for the treatment of adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL) after two or more lines of systemic therapy including a Bruton's tyrosine kinase (BTK) inhibitor.
Tecartus® is additionally indicated for the treatment of adult patients 26 years of age and above with relapsed or refractory (R/R) B-cell precursor acute lymphoblastic leukaemia (ALL).
Explore clinical efficacy and safety data in:
MCL ALLApril 2025 UKI-YES-0065
Adverse events should be reported
Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or via the Yellow Card app (download from the Apple App Store or Google Play Store). Adverse events should also be reported to Gilead to [email protected] or +44 (0) 1223 897500.